195 related articles for article (PubMed ID: 22424015)
1. Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial.
Alli OO; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA; Holmes DR;
Am Heart J; 2012 Mar; 163(3):438-45. PubMed ID: 22424015
[TBL] [Abstract][Full Text] [Related]
2. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
Stone GW; Ellis SG; O'Shaughnessy CD; Martin SL; Satler L; McGarry T; Turco MA; Kereiakes DJ; Kelley L; Popma JJ; Russell ME;
JAMA; 2006 Mar; 295(11):1253-63. PubMed ID: 16531618
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.
Holmes DR; Teirstein P; Satler L; Sketch M; O'Malley J; Popma JJ; Kuntz RE; Fitzgerald PJ; Wang H; Caramanica E; Cohen SA;
JAMA; 2006 Mar; 295(11):1264-73. PubMed ID: 16531619
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.
Ota H; Mahmoudi M; Kitabata H; Torguson R; Chen F; Satler LF; Suddath WO; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2015 Mar; 16(2):84-9. PubMed ID: 25870152
[TBL] [Abstract][Full Text] [Related]
6. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial.
Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
Am Heart J; 2009 Oct; 158(4):e43-50. PubMed ID: 19781402
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
Mehilli J; Byrne RA; Tiroch K; Pinieck S; Schulz S; Kufner S; Massberg S; Laugwitz KL; Schömig A; Kastrati A;
J Am Coll Cardiol; 2010 Jun; 55(24):2710-6. PubMed ID: 20226618
[TBL] [Abstract][Full Text] [Related]
8. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
[TBL] [Abstract][Full Text] [Related]
10. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Pinieck S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schömig A; Mehilli J;
J Am Coll Cardiol; 2010 Jun; 55(23):2536-43. PubMed ID: 20417052
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial.
Violini R; Musto C; De Felice F; Nazzaro MS; Cifarelli A; Petitti T; Fiorilli R
J Am Coll Cardiol; 2010 Feb; 55(8):810-4. PubMed ID: 20170821
[TBL] [Abstract][Full Text] [Related]
12. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
13. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis.
Saia F; Lemos PA; Hoye A; Sianos G; Arampatzis CA; de Feyter PJ; van der Giessen WJ; Smits PC; van Domburg RT; Serruys PW
Catheter Cardiovasc Interv; 2004 Jul; 62(3):283-8. PubMed ID: 15224289
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus-eluting stent implantation versus beta-irradiation for the treatment of in-stent restenotic lesions: clinical and ultrasound results from a randomised trial.
Wiemer M; König A; Rieber J; Sohn HY; Leibig M; Theisen K; Klauss V; Langer C; Lindner O; Horstkotte D; Schiele TM
EuroIntervention; 2011 Jan; 6(6):687-94. PubMed ID: 21205590
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
[TBL] [Abstract][Full Text] [Related]
17. Comparison between sirolimus-eluting stents and intracoronary catheter-based beta radiation for the treatment of in-stent restenosis.
Feres F; Muñoz JS; Abizaid A; Albertal M; Mintz GS; Staico R; Centemero M; Mattos LA; Maldonado G; Tanajura LF; Chaves A; Pinto I; Abizaid AS; Seixas AC; Vaz VD; Sousa A; Sousa JE
Am J Cardiol; 2005 Dec; 96(12):1656-62. PubMed ID: 16360353
[TBL] [Abstract][Full Text] [Related]
18. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis.
Almalla M; Schröder JW; Pross V; Stegemann E; Marx N; Hoffmann R
Am J Cardiol; 2011 Aug; 108(4):518-22. PubMed ID: 21624553
[TBL] [Abstract][Full Text] [Related]
19. Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial.
Kandzari DE; Rao SV; Moses JW; Dzavik V; Strauss BH; Kutryk MJ; Simonton CA; Garg J; Lokhnygina Y; Mancini GB; Yeoh E; Buller CE;
JACC Cardiovasc Interv; 2009 Feb; 2(2):97-106. PubMed ID: 19463409
[TBL] [Abstract][Full Text] [Related]
20. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
